Filing Details
Arbutus Biopharma Corp (NASDAQ:ABUS) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event.
8k filedNASDAQ:ABUS
Arbutus Biopharma Corp (ABUS) Reports Material Event to SEC
Filing Details Arbutus Biopharma Corp (NASDAQ:ABUS) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event. Market Context…
Market Context
Arbutus Biopharma Corp's stock currently trades at $4.74 with a market capitalization of $896.2M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Arbutus Biopharma Corp's stock.
All SEC filings for Arbutus Biopharma Corp are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ABUS Stock Page
Frequently Asked Questions
Where can I read ABUS's SEC filings?
Browse all filings on our ABUS SEC filings page.
What types of SEC filings does Arbutus Biopharma Corp file?
Public companies like Arbutus Biopharma Corp file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.